<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782624</url>
  </required_header>
  <id_info>
    <org_study_id>1276.9</org_study_id>
    <secondary_id>2009-012524-90</secondary_id>
    <nct_id>NCT02782624</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers</brief_title>
  <official_title>Relative Bioavailability of 5 mg BI 10773 Administered Twice Daily Compared to 10 mg BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the influence of different dosage regimen (5 mg twice daily versus 10 mg once
      daily) on the steady state pharmacokinetics and pharmacodynamics of BI 10773 administered
      orally
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma) - AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for 10 mg BI 10773 QD.</measure>
    <time_frame>up to 168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma) - AUC0-24,ss (area under the concentration-time curves of the analyte in plasma at steady-state over two dosing intervals) for 5 mg BI 10773 BID after the morning dose on Day 5.</measure>
    <time_frame>up to 168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C12,N (concentration of analyte in plasma at 12 hours post-drug administration after administration of the Nth dose for the BID regimen) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose for the QD regimen) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) of BI 10773</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg (average concentration of the analyte in plasma at steady state) of BI 10773</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>¿z,ss (terminal half-life of the analyte in plasma at steady state) of BI 10773</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,ss (terminal half-life of the analyte in plasma at steady state) of BI 10773</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval t) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase tau z at steady state following extravascular administration) of BI 10773.</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF (percentage peak-trough fluctuation)</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>5 days of treatment with 5 mg BI 10773 bid until steady state</description>
    <arm_group_label>Treatment A: Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>5 days of treatment with 10 mg BI 10773 qd until steady state</description>
    <arm_group_label>Treatment B: Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Healthy males and females according to the following criteria: Based upon a complete
        medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG,
        clinical laboratory tests

          -  Age = 18 and Age = 50 years

          -  BMI = 18.5 and = 29.9 kg/m2 (Body Mass Index)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation.

        Exclusion criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders 6. History of relevant orthostatic hypotension, fainting spells
             or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs within one month or less than 10 half-lives of the respective drug
             prior to first study drug administration except if a relevant interaction can be ruled
             out

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in
             males)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to the start of study)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms)

          -  A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family
             history of Long QT Syndrome)

        For female subjects:

          -  Positive pregnancy test, pregnancy or planning to become pregnant during the study or
             within 1 month after study completion

          -  No adequate contraception during the study and until 1 month after study completion,
             i.e. not any of the following: implants, injectables, combined oral contraceptives,
             IUD A record of all subjects screened, in- or excluded, will be maintained.
             (intrauterine device), sexual abstinence for at least 1 month prior to enrolment,
             vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or
             surgical sterilisation (including hysterectomy). Females, who do not have a
             vasectomised partner, are not sexually abstinent or surgically sterile will be asked
             to use an additional barrier method (e.g. condom, diaphragm with spermicide)

          -  Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.9.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

